Progress in immunoconjugate cancer therapeutics (Q35099511)

6 August 2017

1 reference

title

Progress in immunoconjugate cancer therapeutics (English)

1 reference

6 August 2017

Gillian Payne

1

1 reference

6 August 2017

1 March 2003

1 reference

6 August 2017

1 reference

6 August 2017

3

1 reference

6 August 2017

3

1 reference

6 August 2017

207-212

1 reference

Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Radioimmunotherapy of non-Hodgkin lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Synthesis and biological evaluation of 2-acyl analogues of paclitaxel (Taxol).

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

High-throughput generation and engineering of recombinant human antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Toxin-labeled monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Tumor therapy with targeted atomic nanogenerators

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Tumor-Specific Novel Taxoid−Monoclonal Antibody Conjugates

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Mylotarg: antibody-targeted chemotherapy comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Breast cancer radiotherapy: safe for all?

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2803%2900057-6

7 January 2021

10.1016/S1535-6108(03)00057-6

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12676579